The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of PX-866 in recurrent glioblastoma.
Marshall W. Pitz
No relevant relationships to disclose
Elizabeth A. Eisenhauer
No relevant relationships to disclose
Mary Valeria MacNeil
No relevant relationships to disclose
Brian Thiessen
No relevant relationships to disclose
David R. Macdonald
No relevant relationships to disclose
Jacob C. Easaw
No relevant relationships to disclose
David Daniel Eisenstat
No relevant relationships to disclose
Ankineedu Saranya Kakumanu
No relevant relationships to disclose
Jeremy Squire
No relevant relationships to disclose
Ming Sound Tsao
No relevant relationships to disclose
Suzanne Kamel-Reid
No relevant relationships to disclose
Aurelie Tassignon
No relevant relationships to disclose
Diana Felice Hausman
Employment or Leadership Position - Oncothyreon
Stock Ownership - Oncothyreon
Warren P. Mason
No relevant relationships to disclose